Spyre Therapeutics Inc. - Asset Resilience Ratio
Spyre Therapeutics Inc. (SYRE) has an Asset Resilience Ratio of 84.34% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Spyre Therapeutics Inc.'s Asset Resilience Ratio has changed over time. See Spyre Therapeutics Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Spyre Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SYRE stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $644.28 Million | 84.34% |
| Total Liquid Assets | $644.28 Million | 84.34% |
Asset Resilience Insights
- Very High Liquidity: Spyre Therapeutics Inc. maintains exceptional liquid asset reserves at 84.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Spyre Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Spyre Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Spyre Therapeutics Inc. (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Spyre Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 86.25% | $670.81 Million | $777.78 Million | +1.83pp |
| 2024-12-31 | 84.42% | $513.66 Million | $608.48 Million | +40.43pp |
| 2023-12-31 | 43.99% | $150.38 Million | $341.86 Million | +14.69pp |
| 2022-12-31 | 29.30% | $20.85 Million | $71.14 Million | -41.64pp |
| 2021-12-31 | 70.94% | $77.99 Million | $109.93 Million | +36.18pp |
| 2020-12-31 | 34.76% | $56.18 Million | $161.62 Million | -28.59pp |
| 2019-12-31 | 63.35% | $52.70 Million | $83.18 Million | -3.61pp |
| 2018-12-31 | 66.96% | $52.05 Million | $77.74 Million | +0.12pp |
| 2017-12-31 | 66.84% | $37.48 Million | $56.08 Million | +43.35pp |
| 2016-12-31 | 23.49% | $15.75 Million | $67.06 Million | +13.74pp |
| 2015-12-31 | 9.75% | $3.77 Million | $38.65 Million | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more